Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 338Neoplasms, Plasma Cell 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Recurrence 50Lymphoma 48Leukemia 39Neoplasms 27Lymphoma, Mantle-Cell 27Burkitt Lymphoma 26Lymphoma, Large B-Cell, Diffuse 23Immunoglobulin Light-chain Amyloidosis 23Lymphoma, Non-Hodgkin 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 14Nausea 12Lymphoma, Extranodal NK-T-Cell 12Lymphoma, B-Cell, Marginal Zone 12Vomiting 11Smoldering Multiple Myeloma 11Prostatic Neoplasms 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Breast Neoplasms 11Renal Insufficiency 10Neoplasm Metastasis 9Lymphoma, Large-Cell, Immunoblastic 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Leukemia, Biphenotypic, Acute 7

Interventions

Amifostine 10Cisplatin 8Radiotherapy 7Etoposide 6Cyclophosphamide 4Carboplatin 4Paclitaxel 3pegfilgrastim 2camrelizumab 2apatinib 2Mitoxantrone 2Filgrastim 2Drug Therapy 2Cytarabine 2sodium thiosulfate 1sargramostim 1pazopanib 1icotinib 1glucarpidase 1etoposide phosphate 1denileukin diftitox 1Vitamin E 1Triptorelin Pamoate 1Tocopherols 1Thiotepa 1Tegafur 1Taxes 1Surgical Procedures, Operative 1Silymarin 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × Dexamethasone × Clear all
NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡